Clinical Trials Logo

Clinical Trial Summary

SUMMARY Rationale: Optimal antibiotic dosing in patients with bacterial infections is of high importance. Underdosing can lead to treatment failure and can promote emergence of antimicrobial resistance, while overdosing may lead to (harmful) side effects. The antibiotic cefuroxime is a second-generation cephalosporin and is frequently used in hospitalized patients. Cefuroxime exhibits, like other cephalosporins, time-dependent killing. The pharmacodynamic target can therefore be best described as the percentage of the dosing interval that the serum concentration remains above the minimum inhibitory concentration (MIC) of the bacteria (T>MIC). Attaining the pharmacokinetic-pharmacodynamic (PK-PD) target of 50%T>MIC is associated with antimicrobial therapeutic efficacy of cefuroxime. Because cefuroxime is almost exclusively excreted through the kidneys, dose reduction of cefuroxime for patients with renal impairment (eGFR<30ml/min/1.73m2) is standard of care. No prospective evidence exists that currently guideline-recommended cefuroxime dosing regimens result in at least 50%T>MIC in adult patients on general wards, especially not in patients with renal impairment receiving a reduced dose of cefuroxime. Objective: To investigate whether the PK-PD target of cefuroxime (50%T>MIC) is attained in the first 24 hours of treatment in adult patients on general wards with adequate and impaired renal function receiving regular and reduced doses of cefuroxime. Study design: Observational, prospective single center cohort study Study population: Adult patients (age ≥ 18 years) on general wards of Noordwest Ziekenhuisgroep (NWZ) receiving cefuroxime as part of standard care. Intervention: Three venapunctures within a period of 72 hours, containing a maximum of 18ml of venous blood in total. Main study parameters: Percentage of patients attaining the cefuroxime PK-PD target of 50%T>MIC. This will be investigated for patients with adequate renal function receiving a regular cefuroxime dose and impaired renal function receiving a guideline recommended reduced dose. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Risks imposed by participation are considered negligible. Three venapunctures, obtaining a maximum of 18 ml venous blood are not expected to cause AEs or SAEs. Participation itself does not bring any benefit as cefuroxime treatment is part of standard care, but the group related benefit could be significant. With the results of this study, current recommended cefuroxime dosing regimens are prospectively validated or an advice to reconsider current guidelines will be obtained.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05200975
Study type Interventional
Source Noordwest Ziekenhuisgroep
Contact Saskia E Zieck, MSc
Phone 0031880857476
Email [email protected]
Status Recruiting
Phase N/A
Start date January 15, 2022
Completion date January 1, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04075344 - Effect of a Infection Control Program on the Reduction of Bacterial Contamination on NG Tube Feeding in RCHEs N/A
Not yet recruiting NCT04484740 - Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue Phase 1
Recruiting NCT05333133 - High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children N/A
Completed NCT03688321 - Probiotic on Prevention of GBS Vaginal Infection During Pregnancy N/A
Completed NCT03244917 - Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias N/A
Recruiting NCT04450680 - Beta-lactam Therapeutic Drug Monitoring in Singapore
Recruiting NCT03752424 - Topical Silver Nanoparticles for Microbial Activity Phase 1
Recruiting NCT04440631 - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Recruiting NCT05150015 - ElastoMeric Infusion Pumps for Hospital AntibioTICs N/A
Recruiting NCT03816956 - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 Phase 3
Terminated NCT03555981 - Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates N/A
Completed NCT03133312 - Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery Phase 4
Recruiting NCT04800575 - Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter N/A
Recruiting NCT03925402 - Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia
Completed NCT03172039 - Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit N/A
Not yet recruiting NCT05223400 - Drug Use Evaluation of Clindamycin in Critical Care Units in Alexandria Main University Hospital
Recruiting NCT03440216 - Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units N/A
Not yet recruiting NCT05542771 - External Validation of the Beta-lactam Target Non-attainment (BATMAN) Risk Score in Adult ICU Patients: a Diagnostic Multivariate Predictive Risk Model
Completed NCT04011657 - Effective Antimicrobial StewaRdship StrategIES (ARIES) N/A
Active, not recruiting NCT05027893 - Complications After Lower Third Molar Surgery N/A